Highlights  Efficacy of bispyridine benzene mGlu5 negative allosteric modulators depends on molecule geometry.
Introduction
Metabotropic glutamate receptors (mGluRs) are class C G Protein-Coupled Receptors (GPCRs) activated by glutamate, the major excitatory neurotransmitter in the central nervous system (CNS). They are widely distributed throughout the CNS, regulating several neuronal and glial functions [1] , and are considered potential targets for the treatment of several neurological disorders [2] . The mGlu receptor family comprises eight subtypes classified in three groups based upon sequence homology and molecular function [3] . In particular, subtype 5 (mGlu 5 ) belongs to group I mGluRs and is mainly postsynaptic. Current research indicates that inactivating mGlu 5 may be an effective treatment for neuropathic and inflammatory pain [4, 5] and may exert a neuroprotective effect on dopaminergic neurons, particularly in animal models of Parkinson's disease and L-DOPA-induced dyskinesia [6] [7] [8] [9] . Furthermore, preclinical and clinical trials have revealed a possible treatment for other diseases such as Fragile-X syndrome [10, 11] , depression [12] and gastro-oesophageal reflux [13] .
The classical approach in controlling the pharmacological activity of mGlu 5 involves the use of orthosteric agonists and antagonists, which compete with glutamate, the endogenous agonist. These orthosteric ligands, e.g. Quisqualate (1) [14] or (S)-MCPG (2) [15] , bind to the mGlu 5 receptor extracellular domain but achieving suitable selectivity for one subtype over another is difficult because of the highly conserved orthosteric binding-site exhibited amongst mGlu-family members [16] .
Allosteric modulators may solve this selectivity issue, since they bind to a less conserved allosteric site in the transmembrane domain, which shows more variation across subtypes [17] . Moreover, allosteric ligands, with lower polarity due to the higher hydrophobicity of the allosteric site, generally allow for better absorption [18] and more efficient crossing of the blood-brain barrier (BBB) [19] . Examples of such ligands include positive allosteric modulators (PAMs) CDPPB (3) [20] and VU0409551/JNJ-46778212 (4) [21] ; and negative allosteric modulators (NAMs) fenobam (5) [22] , MPEP (6) [23] , raseglurant (7) [24] and mavoglurant (8) [25] , with the last having been recently co-crystallized in the allosteric pocket of the mGlu 5 transmembrane domain [26] . [14] , compound 2 is an orthosteric antagonist [15] , compounds 3 and 4 are positive allosteric modulators (PAMs) and compounds 5-11 are negative allosteric modulators (NAMs) [22] [23] [24] [25] [27] [28] [29] [30] . Compounds 6, 7, 11, 12a and 12b are 2-ethynylpyridine derivatives and compounds 9 and 10 are phenylazopyridine derivatives [20, 21] .
Interestingly, many NAMs of mGlu 5 , which usually display an inverse agonist activity, include a terminal pyridine or thiazole with an ethynyl unit at position 2 or 4, respectively [24] . According to recent publications [26, 31] , this ethynyl moiety traverses a narrow channel in the allosteric site of the transmembrane domain, which might explain the predominance of the diaryl alkyne scaffold among mGlu 5 allosteric modulators. However, the presence of a triple bond is not imperative for potent mGlu 5 PAMs and NAMs, since azo-bridged compounds such as SIB-1757 (9) are also mGlu 5 NAMs with potencies in the nanomolar range [27] .
Recently we reported that alloswitch-1 (10), a photoswitchable mGlu 5 NAM with potency in the nanomolar range (IC 50 = 25 nM) and containing a phenylazopyridine, displays reversible photoisomerization from trans-to cis-isomer [28] , which can be translated to reversible activation-deactivation of mGlu 5 receptors in transfected cells, native cell cultures and in vivo [32] .
In fact, trans-alloswitch-1 (10) most likely binds to the mGlu 5 receptor in a very similar fashion to mavoglurant (8) or MPEP (6), as we recently reported [33] , whereas the binding of the cis-isomer is unstable or absent, in agreement with its lower observed activity [28] . In our computational simulations, the position of the azo-bond of the trans isomer occupies exactly the same narrow channel described by Doré et al. [26] , sharing a common binding mode. In addition, alloswitch-1 (10) possesses a high structural resemblance to XGS-RC-009 (11), a recently reported potent (IC 50 = 24 nM) mGlu 5 NAM [29] , and only differs in the spacer between the western aromatic rings: an azo-bond for alloswitch-1 (10) and an ethynyl-bond for XGS-RC-009 (11) . This further indicates the suitability of compounds containing either spacer type for achieving proper NAM activity in the mGlu 5 receptor.
In the present study, we confirm this correlation between azo-bonds and ethynyl-bonds for mGlu 5 NAMs from the functional and binding points of view. For that reason, we selected 1,3-(2-bisPEB) (12a) and 1,4-(2-bisPEB) (12b) [30] , having considered their nanomolar NAM potency and their geometrically defined non-complex structure ( Figure  1) . Thus, we synthesised and characterised the corresponding azo-derivatives with the aim of obtaining new photoswitchable compounds for precise spatiotemporal control of the mGlu 5 receptor.
Results and Discussion

Chemistry
Previously reported compounds 12a and 12b [30] were prepared from 2-ethynylpyridine (13) and the corresponding diiodobenzene 14a-b using a palladium catalysed Sonogashira coupling in moderate to good yields (Scheme 1). A two-step synthetic route yielded the azocompounds 19a and 19b, starting with a Sonogashira coupling of 2-chloropyridine 16 and the corresponding ethynyl aniline 15a-b to give the intermediates 17a and 17b in moderate yields. The following Mills reaction of 17a and 17b with 2-nitrosopyridine 18 in acidic conditions gave compounds 19a and 19b in good yields. Finally, compounds 21a and 21b were also obtained by a single-step synthesis from the Mills reaction between 2-nitrosopyridine 18 and the corresponding diaminobenze 20a-b in moderate to good yields. All the compounds were screened with high performance liquid chromatography (HPLC) coupled to a photodiode array detector (PDA) and a mass spectrometer (MS) to measure the UV-Vis absorption and mass spectra of the compounds (supplementary material). In addition, we were able to chromatographically separate and identify the cis and trans isomers of compounds 19a, 19b, 21a and 21b, since cis-isomers have a characteristic n-π* band at 420-440 nm and a displacement of the characteristic π-π* at shorter wavelengths (supplementary material).
Next, we tested the photoisomerization properties of azocompounds 19a-b and 21a-b with UV-Vis spectroscopy. In the absence of illumination we detected only the transisomer in all cases. To generate the cis-isomers we exposed the azocompound solution in acetonitrile to violet 380-nm-light since this wavelength is optimally located between the π-π* transition of the trans isomers and the minimum between π-π* and n-π* transitions of the cis isomers. Finally, 430-nm-light was used to recover the trans isomers since it is located in the centre of the n-π* transition of the cis-isomers. We were able to detect a nearly complete photoisomerisation of compound 19b, since the profile of the UV-Vis spectrum obtained after violet illumination was the same as that obtained for the cis isomer peak detected by HPLC-PDA-MS (supplementary material). However, for compounds 19a and 21a-b we did not detect satisfactory photoisomerisation after illumination with violet light, in a similar manner to other previously reported bisazocompounds [34] (supplementary material). This indicates that not all azo-compounds display a suitable photoisomerisation response for obtaining a high population of cis isomers under illumination, which is a necessary condition for efficient on/off receptor switching.
Pharmacology
We tested the compounds using an inositol phosphate (IP) accumulation assay in transiently transfected HEK293 cells with mGlu 5. Dose-response curves were generated to evaluate the antagonistic activity using the orthosteric agonist quisqualate and fenobam (5) as an mGlu 5 allosteric inverse agonist reference compound. Whilst compounds 12a and 12b were only tested in dark conditions, the corresponding incubations of compounds 19a, 19b, 21a and 21b were performed in parallel in both dark conditions and under 380-nm-illumination, to evaluate the photoswitching effect of these compounds on mGlu 5 receptor activity. The 1,3-disubstituted compounds 19a and 21a were found to be mGlu 5 NAMs. In comparison with fenobam (5), compound 19a displayed better potency and efficacy whereas compound 21a displayed higher efficacy but 2-fold lower potency. Both 19a and 21a showed similar efficacies to the structurally related compound 12a (1,3-(2-BisPEB)), whose pharmacological properties were previously reported [30, 35] . The replacement of a triple bond in 12a by an azo group in 19a resulted in a 2-fold loss of potency in mGlu 5 , a result which was also observed but to a greater extent (a 13-fold loss) when replacing both ethynyl spacers by N=N in 21a.
The 1,4 substituted compounds 12b, 19b and 21b also displayed NAM activity in mGlu 5 , with lower potency than the corresponding 1,3-disubstituted compounds and, interestingly, with a much lower efficacy, signifying a partial antagonistic efficacy, which we have attributed to the different substitution pattern at the central benzene ring in the 2-ethynylpyridines or the 2-azopyridines, respectively ( Figure 2 and Table 1) . Interestingly, 1,3-disubstituted compounds display a similar efficacy, or even a bit higher than fenobam (5), a classic allosteric inverse agonist [22] , while 1,4-disubstituted compounds only partially antagonized the effect of quisqualate in mGlu 5 . Moreover, the potencies (IC 50 ) of the 1,4-isomers were found to be within a similar range as the 1,3-isomers.
IC 50 As anticipated from the photoisomerisation experiments, the response of the compounds tested under different illumination conditions was not efficient enough to provide a useful light-dependent control of mGlu 5 activity in cell assays. Upon illumination at 380 nm, we detected successful receptor photoswitching behaviour for compound 19b, which was a partial antagonist as a trans-isomer but experiences a 3-fold loss in potency and 15% loss in efficacy under violet illumination (mainly cisisomer) ( Figure 3 and Table 1 ). The photoinduced potency shifts (PPS) [36] of the dose response curves with the azo-compounds 19a and 21a,b were not sufficient to achieve useful on/off receptor photoswitching. This result was probably due to the compounds intrinsic molecular photochemical properties, which do not allow for a clear-cut difference in the induction of different populations of the cis/trans isomers at the wavelengths used. Another possible explanation for this lack of photoactivity could be an insufficient difference in the affinity of the cis and trans isomers for the receptor, which would result in low stability of the on/off states upon binding. This reflects the necessary combination of photochemical and pharmacological properties of the azo compounds for achieving an effective photoswitching of receptor activity in cell assays or in vivo applications [36] .
After examination of the results obtained, we were particularly interested in the reasons behind the mGlu 5 efficacy differences observed for the 1,4 and 1,3 positional isomers (measured by the asymptotic minimum effects of the dose-response curves on the yaxis), which occur without significantly altering their location along the x-axis (IC 50 values). We hypothesized that this could be due to different binding modes in the transmembrane domain of the mGlu 5 receptor. The high homology between isomers and similarity of the trans-azo and ethynyl bonds, both from the structural and geometrical points of view, result in compounds with very rigid scaffolds where the aromatic rings are either in angular or linear arrangements. Therefore, the binding modes of each geometrical type may be significantly different, since these molecules do not have the flexibility needed to rearrange their scaffold in order to bind in the same pose in the same receptor pocket. To verify this hypothesis, we performed some computational docking.
In silico binding model
To explore the possible binding modes of compounds 12a-b, 19a-b and 21a-b, each compound was docked into the crystal structure of mGlu 5 (PDB id 4OO9, minus its mavoglurant co-crystallized ligand). For each respective docking, the top-ranked protein-ligand complex was energy-minimized to optimize intermolecular interactions.
From the results shown in Figure 4 , the 1,3-compounds are able to bind at the bottom of the allosteric pocket because their structures are easily accommodated within the distinctive angular binding-site, displaying a similar binding pose to the previously cocrystallized mGlu 5 NAMs: mavoglurant (in PDB id 4OO9 [26] ) and HTL14242 (in PDB id 5CGD [37] ). In doing so, each 1,3-compound achieves a favourable docking score ( Table 2) , making an H-bond with S809 on TM7 (after energy minimization), and in the case of 19a and 21a, an additional H-bond with N747 on TM5. However, the 1,4-compounds are unable to bind at the bottom of the allosteric pocket (at least in the mGlu 5 crystal structure of PDB id 4OO9), as they are unable to accommodate their structures within the angular binding-site. Instead, they bind higher in the pocket with a pose similar to that observed with the co-crystallized ligand FITM in the crystal structure of mGlu 1 (PDB id: 4OR2 [38] ). As a result of this higher binding pose, the 1,4-compounds achieve much less favourable docking scores ( Table 3 ) and are unable to make an H-bond with S809 on TM7 or any other residue in the allosteric pocket. Although this higher binding pose is apparently functional in terms of mGlu 1 allosterism, it is unlikely to be functional in mGlu 5 , as reflected by the low docking scores observed here (indicating a poor fit) and by experimental data (including current mGlu 5 crystal structures) [26, 37] , which suggests S809 interaction is critical for correct mGlu 5 NAM functionality [35] . Table 2 . Docking scores for six compounds in two conformations of mGlu5 (original crystal structure and a computationally-generated alternative). Three angular-shaped 1,3-compounds: 12a, 19a and 21a, and three linear 1,4-compounds: 12b, 19b and 21b.
In recognition of the fact that GPCRs are flexible dynamic receptors, an alternative conformation of mGlu 5 was utilised to re-dock the 1,4-compounds in an attempt to A B C identify better binding poses at the bottom of the allosteric pocket (more similar in nature to current co-crystallized mGlu 5 NAMs). This alternative receptor conformation was derived from the original mGlu 5 crystal structure (PDB id 4OO9) through computational conformational sampling performed previously [33] . This process results in a relatively subtle adjustment of side-chain packing between TM6 and TM7 but, more significantly, an enlargement and alteration of the binding pocket from an angular shape to a wider linear shape. Using this alternative receptor conformation, the 1,4-compounds instead dock at the bottom of the allosteric pocket, making an H-bond with S809 on TM7 (Figure 5 ), the residue designated as important for interaction with mGlu 5 NAMs [35] , and packing against hydrophobic residues on TM5 (e.g. L744) and TM6. In accordance with this changed binding-mode, the docking scores of the 1,4-compounds are improved compared to the previous dockings in the original crystal structure (PDB id 4OO9) ( Table 2 ). However, it should be noted that this alternative receptor conformation is perhaps not as readily accessible in energetic terms as the original crystal structure conformation, potentially affecting the pharmacological activity of the 1,4-compounds.
Concluding remarks
We synthesised four derivatives of the mGlu 5 NAMs 1,3-(2-BisPEB) and 1,4-(2-BisPEB) via azologisation [39] of one or two ethynyl groups, which maintain similar pharmacological properties to the previous reported isosteres [30] , including similar potencies.
Despite the similar potencies among the compounds tested, we found substantial differences in their antagonistic efficacies on the mGlu 5 receptor: compounds with 1,3-substitution displayed an inverse agonist efficacy similar to the reference compound fenobam, whereas compounds with 1,4-substitution displayed partial antagonistic effects.
Computational docking in the mGlu 5 crystal structure [26] revealed the angular-shaped 1,3-substituted compounds bind in a very similar pose to the co-crystallised inverse agonist mavoglurant, whereas the linear 1,4-substituted compounds bind in a different pose, unlikely to be functional and with a concomitantly worse docking score. However, an alternative conformation of the mGlu 5 transmembrane domain might adapt to these linear-shaped compounds in a functional-like pose, which may be responsible for their partial antagonism behaviour.
The discovery of a molecular switch from full allosteric inverse agonists to partial allosteric antagonists is of high interest, since recent publications have reported the advantageous properties of partial mGlu 5 NAMs [40, 41] , which might avoid on-target side-effects of full mGlu 5 inhibition by classical allosteric inverse agonists [42, 43] . Therefore, our approach based on changing substituent positions of molecularly rigid mGlu 5 NAMs may be useful for discovering new partial mGlu 5 NAMs with safer pharmacological profiles and better drug design outcomes.
Experimental Section Chemistry
All the chemicals and solvents were provided from commercial suppliers and used without purification, except the anhydrous solvents, which were treated previously through a system of solvent purification (PureSolv), degasified with inert gases and dried over alumina or molecular sieve (DMF). Dimethylisopropylamine (DMAP) and triethylamine (TEA) were also dried over alumina. Thermo Ultimate 3000SD (Thermo Scientific Dionex) coupled to a photodiode array detector and a mass spectrometer LTQ XL ESI-ion trap (Thermo Scientific) (HPLC-PDA-MS); 5 µL of sample 0.25 mM in a mixture DMSO/AcN 1:9 were injected, using an Acquity UPLC BEH C18 column (Waters) 1.7 μm 2.1x100 mm (SN 021532354157 76) at 30ºC. The mobile phase used was a mixture of A = NH 4 HCO 3 aqueous buffer 10 mM pH=7.4 and B = acetonitrile (AcN) with the method described as follows: flow 0.3 mL/min, 5%B-100%B 3 min, 100%B 5 min, total runtime 15 min; purity is given as % of absorbance of the cis and trans isomers at 254 nm; UV-Vis spectra were collected every 0.2 s between 650 and 275 nm and bands are % of maximal absorbance; data from mass spectra were analysed by electrospray ionization in positive and negative mode every 0.3 s between 50 and 1000 Da and peaks are given m/z (% of basis peak). High-resolution mass spectra (HRMS) and elemental composition were analysed by FIA (flux injected analysis) with ultra-high performance liquid chromatography (UPLC) Aquity (Waters) coupled to LCT Premier orthogonal accelerated time of flight mass spectrometer (TOF) (Waters). Data from mass spectra were analysed by electrospray ionization in positive and negative mode. Spectra were scanned between 50 and 1500 Da with values every 0.2 s and peaks are given m/z (% of basis peak).
1,3-bis(pyridin-2-ylethynyl)benzene 12a:
General procedure A: 2-ethylpyridine 13 (35 µL, 0.35 mmol) and dry diisopropylethylamine (DIPEA) (0.1 ml, 0.57 mmol) were added to a dispersion of 1,3-diiodobenzene 14a (46 mg, 0.14 mmol), copper(I) iodide (2 mg, 0.01 mmol) and bis(triphenylphosphine) palladium (II) chloride (5.4 mg, 0.01 mmol) in dry dimethyl formamide (DMF) (1 mL) in a Schlenk flask with argon atmosphere at room temperature. The mixture was stirred at 50ºC for 5 hours. The reaction mixture was diluted in EtOAc (15 mL) and washed with aqueous Na 2 CO 3 1 N (10 mL), saturated NaHCO 3 (10 mL), water (10 mL) and brine (10 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo. The residue was purified through flash chromatography using Biotage Isolera equipment (SNAP KP-C18-HS 12g, A=H 2 O, B=MeCN; 0%B 5CV, 0%B-1%B 2CV, 1%B-4%B 2.5 CV, 4%B 1.5CV, 4%B-7%B 6CV, 7%B-9%B 0.5CV, 9%B-100%B 2 CV, 100%B 5CV). The title product 12a was obtained as brown colour solid (34 mg) with an 87% yield, mp 89.9-91.3ºC. 3-(pyridin-2-ylethynyl)aniline 17a: General procedure B: 2-chloropyridine 16 (0.13 mL, 1.37 mmol), 3-ethynylaniline 15a (0.24 mL, 2.13 mmol) and dry triethylamine (TEA) (0.76 ml, 5.46 mmol) were added to a dispersion of copper(I) iodide (13 mg, 0.07 mmol) and bis(triphenylphosphine) palladium (II) chloride (48 mg, 0.07 mmol) in dry dimethyl formamide (DMF) (8 mL) in a Schlenk flask with argon atmosphere at room temperature. The mixture was stirred at 60ºC for 4 hours. The reaction mixture was diluted in EtOAc (100 mL) and washed with aqueous Na 2 CO 3 1 N (50 mL), saturated NaHCO 3 (50 mL), water (50 mL) and brine (50 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo. The residue was purified through silica flash chromatography (DCM and DCM + 1% MeOH) to afford the title compound 17a as brown thick oil (80 mg, 30% yield). 
2-((4-(pyridin-2-yldiazenyl)phenyl)ethynyl)pyridine 19b:
General procedure C was used with one drop of AcOH, 18 (11 mg, 0.10 mmol) and 17b (13 mg, 0.07 mmol) in DCM (1 mL). The obtained residue was purified through flash chromatography using Biotage Isolera equipment (SNAP KP-C18-HS 12g, A= H 2 O B=MeOH; 0%B 3CV, 0%B-60%B 5CV, 60%B-85%B 8CV, 85%B-100%B 1CV, 100%B 8CV 
Pharmacology
HEK 293 cells were cultured and transfected by electroporation as previously described for expression of all rat mGlu receptors [44] . To maintain ambient glutamate at minimal concentrations, the excitatory amino acid transporter 1 (EAAC1) was cotransfected. All receptors contained an HA tag in their N-terminus to monitor their cell surface expression by ELISA. Once transfected, cells were seeded in black clearbottom 96-well plates at a concentration of 1.5 × 105 cells/well. At least 4h before the experiment, we changed the medium to glutamate-free DMEM GlutaMAX-I (Thermo Fisher Scientific). The day after, we estimated IP accumulation using the IP-One HTRF kit (Cisbio Bioassays) according to the manufacturer's instructions. Cells were stimulated to induce IP accumulation while being treated with test compounds for 30 min, at 37°C and 5% CO 2 , and placed over an LED plate [28] (FCTecnics) at a distance of 2-3 cm for continuous illumination. To allow stimulation in both dark conditions and violet light illumination, two-thirds of the 96-well plate bottom was covered with aluminium foil. To avoid effects derived from the fast relaxation of azocompounds in aqueous solution after the 30-min stimulation, we washed cells once in stimulation buffer alone before continuing with the lysis step of the assay protocol. For fluorescence readings with a RUBYstar HTRF HTS microplate reader (BMG Labtech), we transferred cell lysates to a black opaque-bottom 96-well plate. Dose-response data from IP accumulation assays were first normalized by the dose-response to reference allosteric modulator fenobam in both dark and illuminated conditions and then fitted with a standard Hill equation using GraphPad Prism version 6.0.
Computational
The molecular structures of six compounds: 12a-b, 19a-b, 21a-b in trans-isomer state were constructed with Maestro version 9.8 (Schrӧdinger Release 2014). Each compound was docked into the transmembrane domain crystal structure of mGlu 5 (PDB id 4OO9, minus co-crystallized mavoglurant) using AutoDock4.2 with default parameters [45] . For each respective docked compound, the top-ranked complex (according to AutoDock docking score) was energy-minimized in the Amber14SB force-field [46] using CHIMERA [47] to optimize protein-ligand interactions. The three linear 1,4-compounds in trans-isomer state: 12b, 19b and 21b were also docked (using same parameters) into an alternative mGlu 5 receptor conformation, previously derived from the mGlu 5 crystal structure (PDB id 4OO9) by using a conformational sampling technique [33] .
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